How to Use an Article About Therapy or Prevention

You are working as an internal medicine resident in a rheumatology rotation and are seeing a 19 year-old woman who has had systemic lupus erythematosus diagnosed on the basis of a characteristic skin rash, arthritis, and renal disease. A renal biopsy has shown diffuse proliferative nephritis. A year ago, her creatinine was 140 micromoles/litre, six months ago 180, and in a blood sample taken a week before this clinic visit, 220. Over the last year she has been taking prednisone, and over the last six months, cyclophosphamide, both in appropriate doses.

[1]  D L Sackett,et al.  An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.

[2]  D. Sackett,et al.  The Ends of Human Life: Medical Ethics in a Liberal Polity , 1992, Annals of Internal Medicine.

[3]  Marie E. Latulippe,et al.  A controlled trial of corticosteroid injections into facet joints for chronic low back pain. , 1991, The New England journal of medicine.

[4]  B. Kramer,et al.  Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial. , 1983, The Journal of pediatrics.

[5]  C. Viscoli,et al.  Treatment adherence and risk of death after a myocardial infarction , 1990, The Lancet.

[6]  Gordon H. Guyatt,et al.  Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. , 1993, JAMA.

[7]  D. Sackett,et al.  Functional status changes following medical or surgical treatment for cerebral ischemia. Results of the extracranial-intracranial bypass study. , 1987, JAMA.

[8]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[9]  Douglas G. Altman,et al.  Statistics with confidence: Confidence intervals and statistical guidelines . , 1990 .

[10]  T C Chalmers,et al.  Bias in treatment assignment in controlled clinical trials. , 1983, The New England journal of medicine.

[11]  W. Asher,et al.  Effect of human chorionic gonadotrophin on weight loss, hunger, and feeling of well-being"2 , 1973 .

[12]  A. Detsky,et al.  When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. , 1985, Archives of internal medicine.

[13]  Robert Lemery,et al.  Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. , 1992, The New England journal of medicine.

[14]  K. Matthews,et al.  Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. , 1990, BMJ.

[15]  E. Lewis,et al.  A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. , 1992, The New England journal of medicine.

[16]  E. Lewis,et al.  Progression and Remission of Renal Disease in the Lupus Nephritis Collaborative Study , 1992, Annals of Internal Medicine.

[17]  M. Gardner,et al.  Statistical guidelines for contributors to medical journals , 1983 .

[18]  J D Emerson,et al.  An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials. , 1990, Controlled clinical trials.

[19]  G H Guyatt,et al.  Effect of encouragement on walking test performance. , 1984, Thorax.

[20]  R. Fuller,et al.  Compliance with disulfiram treatment of alcoholism. , 1983, Journal of chronic diseases.

[21]  L A Moyé,et al.  The cardiac arrhythmia suppression trial. Casting suppression in a different light. , 1995, Circulation.

[22]  S M Nazarian,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.

[23]  T. Berl,et al.  Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. , 1991, Annals of internal medicine.

[24]  G. Guyatt,et al.  Controlled trial of respiratory muscle training in chronic airflow limitation. , 1992, Thorax.

[25]  G. Hogarty,et al.  Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. , 1974, Archives of general psychiatry.

[26]  G H Guyatt,et al.  A Consumer's Guide to Subgroup Analyses , 1992, Annals of Internal Medicine.

[27]  F. Mosteller,et al.  How study design affects outcomes in comparisons of therapy. I: Medical. , 1989, Statistics in medicine.

[28]  D M Eddy,et al.  Clinical policies and the quality of clinical practice. , 1982, The New England journal of medicine.

[29]  M. Dalakas,et al.  Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. , 1992, The New England journal of medicine.

[30]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[31]  G. Raskob,et al.  Hemorrhagic complications of anticoagulant treatment. , 1992, Chest.

[32]  G. Guyatt,et al.  Users' guides to the medical literature. , 1993, JAMA.